RabMAb

Anti-Cyclin D1 antibody [SP4], prediluted (ab21699)

Overview

  • Product nameAnti-Cyclin D1 antibody [SP4], prediluted
    See all Cyclin D1 primary antibodies
  • Description
    Rabbit monoclonal [SP4] to Cyclin D1, prediluted
  • Specificityab21699 recognises Cyclin D1.
  • Tested applicationsIHC-P, IHC-Fr, WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A synthetic peptide from C-terminus of human cyclin D1.

  • Positive control
    • Breast carcinoma, mantle cell lymphoma. MCF7 cell lysate.

Properties

Applications

Our Abpromise guarantee covers the use of ab21699 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P
IHC-Fr
WB
  • Application notesIHC-P: Use neat. Perform heat mediated antigen retrieval before commencing with IHC staining protocol; in particular: perform high temperature antigen unmasking with 10 mM citrate buffer, pH 6.0.
    Suggested primary antibody incubation period: 30 minutes at room temperature.
    IHC-Fr: Use neat.
    Note: samples are acetone fixed.
    Suggested primary antibody incubation period: 30 minutes at room temperature.


    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionEssential for the control of the cell cycle at the G1/S (start) transition.
    • Involvement in diseaseNote=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
      Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
      Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
    • Sequence similaritiesBelongs to the cyclin family. Cyclin D subfamily.
    • Post-translational
      modifications
      Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
      Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
    • Cellular localizationNucleus.
    • Information by UniProt
    • Database links
    • Alternative names
      • AI327039 antibody
      • B cell ccl/lymphoma 1 antibody
      • B cell CLL/lymphoma 1 antibody
      • B cell leukemia 1 antibody
      • B cell leukemia 1 antibody
      • B cell lymphoma 1 protein antibody
      • B-cell lymphoma 1 protein antibody
      • BCL 1 antibody
      • BCL-1 antibody
      • BCL-1 oncogene antibody
      • BCL1 antibody
      • BCL1 oncogene antibody
      • CCND 1 antibody
      • CCND1 antibody
      • CCND1 protein antibody
      • CCND1/FSTL3 fusion gene, included antibody
      • CCND1/IGHG1 fusion gene antibody
      • CCND1/IGHG1 fusion gene, included antibody
      • CCND1/IGLC1 fusion gene, included antibody
      • CCND1/PTH fusion gene, included antibody
      • CCND1_HUMAN antibody
      • cD1 antibody
      • Cyl 1 antibody
      • D11S287E antibody
      • G1/S specific cyclin D1 antibody
      • G1/S-specific cyclin-D1 antibody
      • Parathyroid adenomatosis 1 antibody
      • PRAD1 antibody
      • PRAD1 oncogene antibody
      • U21B31 antibody
      see all

    Anti-Cyclin D1 antibody [SP4], prediluted images

    • Anti-Cyclin D1 antibody [SP4], prediluted (ab21699) at 1/25 dilution + MCF7 cell lysate

      Predicted band size : 34 kDa
    • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human Mantle Cell Lymphoma tissue, staining Cyclin D1 with ab21699 at 1/100 dilution.
    • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human tonsil tissue, staining Cyclin D1 with ab21699 at 1/100 dilution.
    • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human endometrial adenocarcinoma tissue, staining Cyclin D1 with ab21699 at 1/100 dilution.
    • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human lung adenocarcinoma tissue, staining Cyclin D1 with ab21699 at 1/100 dilution.

    References for Anti-Cyclin D1 antibody [SP4], prediluted (ab21699)

    ab21699 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab21699.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"